Comparative Pharmacology
Head-to-head clinical analysis: LUMIZYME versus REVCOVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMIZYME versus REVCOVI.
LUMIZYME vs REVCOVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
Recombinant adenosine deaminase (ADA) enzyme replacement therapy; degrades adenosine and deoxyadenosine, reducing toxic metabolites and restoring immune function.
5 mg/kg administered intravenously once every 2 weeks.
25 mg/kg body weight administered intramuscularly once weekly.
None Documented
None Documented
Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes.
Terminal elimination half-life is approximately 3-6 months (mean ~100 days) in patients with PEG-ADA deficiency; clinical context: sustained enzyme replacement allows weekly or biweekly dosing.
Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine.
Renal excretion of unchanged drug and metabolites: approximately 100% eliminated renally; no significant biliary/fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy